Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 8/20 | 0.66 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.65 |
| ▸ | QDPR | P09417 | 3/20 | 0.54 |
| ▸ | KHK | P50053 | 2/20 | 0.52 |
| ▸ | HTR7 | P34969 | 3/20 | 0.47 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30431801 | 1.00 | HTR2C (0.66) | HTR2CSIGMAR1QDPRKHKHTR7 | |
| Hydrochloric Acid SCHEMBL9311920 | 0.98 | HTR2C (0.67) | HTR2CSIGMAR1QDPRKHKHTR7 | |
| SCHEMBL14904894 | 0.90 | HTR2C (0.54) | HTR2CSIGMAR1QDPRKHKHTR7 | |
| SCHEMBL15804315 | 0.85 | HTR7 (0.48) | HTR2CSIGMAR1KHKHTR7 | |
| SCHEMBL5319444 | 0.82 | SIGMAR1 (0.57) | HTR2CSIGMAR1QDPRKHKHTR6 | |
| SCHEMBL4791120 | 0.81 | SIGMAR1 (0.79) | HTR2CSIGMAR1QDPRKHKHTR7 | |
| SCHEMBL7955514 | 0.80 | QDPR (0.55) | HTR2CSIGMAR1QDPRKHK | |
| SCHEMBL4671168 | 0.80 | HTR2C (0.66) | HTR2CSIGMAR1QDPRKHKHTR7 | |
| Hydrochloric Acid SCHEMBL4793458 | 0.79 | HTR2C (0.79) | HTR2CSIGMAR1QDPRHTR7HTR6 | |
| SCHEMBL21228136 | 0.79 | HTR2C (0.66) | HTR2CSIGMAR1QDPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017038909-A1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-09 | — | — | WO | disclosed |
| US-9273040-B2 | Benzoxazolinone compounds with selective activity in voltage-gated sodium channels | MERCK SHARP & DOHME CORP. (US) | 2016-03-01 | — | — | US | disclosed |
| US-20140303143-A1 | BENZOXAZOLINONE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME LLC | 2014-10-09 | — | — | US | disclosed |
| WO-2013063459-A1 | BENZOXAZOLINONE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME CORP. (US) | 2013-05-02 | — | — | WO | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7700591-B2 | Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors | MERCK & CO., INC. (US) | 2010-04-20 | — | — | US | disclosed |
| WO-2008015271-A1 | PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THE USE AS A MEDICINE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-07 | — | — | WO | disclosed |
| US-20080032998-A1 | Pyrazolopyrimidines, a process for their preparation and their use as medicine | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-07 | — | — | US | disclosed |
| US-7297799-B2 | Preparation of benzoylalkyl-1,2,3,6-tetrahydropyridines and use thereof | SANOFI-AVENTIS (FR) | 2007-11-20 | — | — | US | disclosed |
| US-5157035-A | Viricides | JANSSEN PHARMACEUTICA N. V. (BE) | 1992-10-20 | — | — | US | disclosed |
| US-5001125-A | Anti-virally active pyridazinamines | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-03-19 | — | — | US | disclosed |
| EP-0156433-B1 | ANTI-VIRALLY ACTIVE PYRIDAZINAMINES | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-02-27 | — | — | EP | disclosed |
| US-4914094-A | CARBOSTYRIC OR BENZOXAZINE DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-04-03 | — | — | US | disclosed |
| EP-0226441-A2 | Preparation of pharmaceutical compositions for the treatment of hypoxia | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-06-24 | — | — | EP | disclosed |
| EP-0156433-A2 | Anti-virally active pyridazinamines | JANSSEN PHARMACEUTICA N.V. (BE) | 1985-10-02 | — | — | EP | disclosed |
| US-4166853-A | Antihypertensive 7-trifluoromethyl-4-aminoquinolones | THE UPJOHN COMPANY (US) | 1979-09-04 | — | — | US | disclosed |
| US-4077958-A | ANTIDEPRESSANTS | E. R. SQUIBB & SONS, INC. (US) | 1978-03-07 | — | — | US | disclosed |
| US-4007191-A | ANTIDEPRESSANT | E. R. SQUIBB & SONS, INC. (US) | 1977-02-08 | — | — | US | disclosed |
| US-3935227-A | ANTIDEPRESSANTS, ANTIANXIETY, ANTIINFLAMMATORY AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1976-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303143-A1 | BENZOXAZOLINONE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | SCN7A, SCN1A, CACNA1E | HTR2C 476/4885SIGMAR1 663/4885QDPR 1646/4885 |
| US-20080032998-A1 | Pyrazolopyrimidines, a process for their preparation and their use as medicine | GRM5, GRM1, GRIK5 | HTR2C 222/4885SIGMAR1 243/4885QDPR 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.